The capabilities are genuinely differentiated: a) ADC: Filed 3 payload DMFs in FY26, completed first cGMP bioconjugation campaign at NJ Bio (US facility), expanding with $10 Mn capex for Phase 2/validation readiness, traction in exatecan-linked platforms b) Oligonucleotide : cGMP building block facility under validation through the Sapala platform, follow-on purchase orders received c) Small Molecule CDMO: 140+ active projects, 70%+ from commercial products, 90%+ reload conversion rate d) Phase 3 pipeline: 10 programs including 1 under priority review and 1 awaiting clinical data readout However, FY26 was operationally challenging
removing the medication allows those neural patterns to revert
For type 2 diabetes, most patients stop at 0.51.0 mg
Wang et al., 2021), but in addition, we have also noticed a significant increase in GLP-1 secretion in the pancreatic islets, which has been ignored in previous studies
Model Description The full model for subcutaneous administration was a model with first-order absorption, two-compartment disposition and first-order elimination, whereas intravenous data were modelled as a bolus injection into the central compartment
Overweight and obesity: a brief challenge on prevalence, complications and physical activity among men and women
